New therapies for type 2 diabetes: What place for incretin-based agents and rimonabant compared to the previous ones?

被引:4
作者
Halimi, S. [1 ]
Debaty, I. [1 ]
Villaret, L. [1 ]
Muller, M. [1 ]
机构
[1] CHU Grenoble, Serv Diabetol Endocrinol Nutr, F-38043 Grenoble, France
来源
REVUE DE MEDECINE INTERNE | 2008年 / 29卷 / 11期
关键词
Type; 2; diabetes; Insulin-secretion; GLPI; DPP4; inhibitors; Sitagliptin; Vidagliptin; Exenatide; Liraglutide;
D O I
10.1016/j.revmed.2008.05.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment of type 2 diabetes (T2DM) is based on lifestyle changes and oral antidiabetic agents or insulin. The UKPDS Study has confirmed metformin (Met) as the initial monotherapy. Accordingly, Met is widely regarded as the first drug of choice for most patients with T2DM. Safety and efficacy of sulphonylureas (SU) have been confirmed by several clinical trials. Recently. thiazolidinediones (TZD) have addressed some aspects of insulin-resistance that characterized several T2DM patients. However, SU and TZD are associated with various side effects that limit their use in many patients. New agents have been recently developed which potentiate the activity of the incretin (GLPI). GLPI, a gut hormone secreted in response to meal ingestion. is rapidly degraded by dipeptidylpeptidase-4 (DPP-4). GLPI enhances insulin secretion and inhibits glucagon secretion ill it glucose-dependent manner, delays gastric emptying and, in animal studies, preserves beta-cell mass by reducing apoptosis and stimulates of P-cell proliferation. GLPI levels are abnormally low in T2DM patients. Two classes of agents based on GLPI have been launched: DPP-4 inhibitors and DPP-4 resistant GLPI analogues. Randomized studies confirmed their efficacy to improve glycemic control in T2DM patients. Orally administered DPP-4 inhibitors reduce HbA 1c by 0.5-1.1%, without hypoglycaemic events and no weight gain. The sub-cutaneous injected GLPI analogues (exenatide and liraglutide) show larger reductions in HbA 1c by 0.8-1.7% and weight loss but are associated with gastrointestinal side effects contributing to a significant treatment interruption. Several studies support the use of DPP-4 inhibitors in combination with Met as a promising second line treatment. (C) 2008 Publie par Elsevier Masson SAS.
引用
收藏
页码:881 / 890
页数:10
相关论文
共 60 条
  • [1] *AFSSAPS HAS, 2007, DIABETES METAB, V33, pIS1
  • [2] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
    Amori, Renee E.
    Lau, Joseph
    Pittas, Anastassios G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02): : 194 - 206
  • [3] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Aschner, Pablo
    Kipnes, Mark S.
    Lunceford, Jared K.
    Sanchez, Matilde
    Mickel, Carolyn
    Williams-Herman, Debora E.
    [J]. DIABETES CARE, 2006, 29 (12) : 2632 - 2637
  • [4] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    [J]. GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [5] Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
    Blonde, L.
    Klein, E. J.
    Han, J.
    Zhang, B.
    Mac, S. M.
    Poon, T. H.
    Taylor, K. L.
    Trautmann, M. E.
    Kim, D. D.
    Kendall, D. M.
    [J]. DIABETES OBESITY & METABOLISM, 2006, 8 (04) : 436 - 447
  • [6] Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
    Bolen, Shari
    Feldman, Leonard
    Vassy, Jason
    Wilson, Lisa
    Yeh, Hsin-Chieh
    Marinopoulos, Spyriclon
    Wiley, Crystal
    Selvin, Elizabeth
    Wilson, Renee
    Bass, Eric B.
    Brancati, Frederick L.
    [J]. ANNALS OF INTERNAL MEDICINE, 2007, 147 (06) : 386 - 399
  • [7] Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    Bosi, Emanuele
    Camisasca, Riccardo Paolo
    Collober, Carole
    Rochotte, Erika
    Garber, Alan J.
    [J]. DIABETES CARE, 2007, 30 (04) : 890 - 895
  • [8] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    Charbonnel, Bernard
    Karasik, Avraham
    Liu, Ji
    Wu, Mei
    Meininger, Gary
    [J]. DIABETES CARE, 2006, 29 (12) : 2638 - 2643
  • [9] Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
    Christensen, Robin
    Kristensen, Pernelle Kruse
    Bartels, Else Marie
    Blidda, Henning
    Astrup, Arne
    [J]. LANCET, 2007, 370 (9600) : 1706 - 1713
  • [10] Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus
    Colucciello, M
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (09) : 1273 - 1275